Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for DICE Therapeutics, Inc. (DICE : NSDQ)
 
 • Company Description   
DICE Therapeutics Inc. is a biopharmaceutical company. Its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. DICE Therapeutics Inc. is based in SOUTH SAN FRANCISCO, Calif.

Number of Employees: 32

 
 • Price / Volume Information   
Yesterday's Closing Price: $29.08 Daily Weekly Monthly
20 Day Moving Average: 188,833 shares
Shares Outstanding: 38.23 (millions)
Market Capitalization: $1,111.76 (millions)
Beta:
52 Week High: $40.50
52 Week Low: $23.16
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -15.83% -13.21%
12 Week % %
Year To Date % %
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
279 E. GRAND AVENUE SUITE 300 LOBBY B
-
SOUTH SAN FRANCISCO,CA 94080
USA
ph: 650-566-1402
fax: -
investors@dicetx.com http://www.dicemolecules.com
 
 • General Corporate Information   
Officers
J. Kevin Judice - Chief Executive Officer
Richard Scheller - Chairman
Scott Robertson - Chief Business and Financial Officer
Jim Scopa - Director
Jake Simson - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 23345J104
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 09/01/21
Next Expected EPS Date: 02/11/22
Share - Related Items
Shares Outstanding: 38.23
Most Recent Split Date: (:1)
Beta:
Market Capitalization: $1,111.76 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.58 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.90 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 02/11/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
09/30/21 - -
06/30/21 - -
03/31/21 - -
ROA
09/30/21 - -
06/30/21 - -
03/31/21 - -
Current Ratio
09/30/21 - -
06/30/21 - -
03/31/21 - -
Quick Ratio
09/30/21 - -
06/30/21 - -
03/31/21 - -
Operating Margin
09/30/21 - -
06/30/21 - -
03/31/21 - -
Net Margin
09/30/21 - -
06/30/21 - -
03/31/21 - -
Pre-Tax Margin
09/30/21 - -
06/30/21 - -
03/31/21 - -
Book Value
09/30/21 - -
06/30/21 - -
03/31/21 - -
Inventory Turnover
09/30/21 - -
06/30/21 - -
03/31/21 - -
Debt-to-Equity
09/30/21 - -
06/30/21 - -
03/31/21 - -
Debt-to-Capital
09/30/21 - -
06/30/21 - -
03/31/21 - -
 

Powered by Zacks Investment Research ©